XORTX Therapeutics Inc.
Business
XORTX Therapeutics is a late clinical-stage biotechnology company developing therapies that modulate aberrant purine and uric acid metabolism. The company is advancing four proprietary product candidates: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 for acute kidney injury associated with respiratory virus infection, and XRx-225 for type 2 diabetic nephropathy. All programs are based on novel formulations of oxypurinol, a xanthine oxidase inhibitor. XORTX pursues regulatory approval via the FDA's 505(b)(2) pathway in the United States and through the European Medicines Agency's Centralized Procedure.
Summary from 20-F filed 2026-03-20
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | — |
| Total assets | $2.68M |
| Total liabilities | $599.1K |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is XORTX Therapeutics Inc.'s CIK number?
XORTX Therapeutics Inc.'s SEC CIK number is 0001729214 (1729214). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find XORTX Therapeutics Inc.'s SEC filings?
All of XORTX Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.